Skip to main content
SpringerLink
Log in

Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease

  • Chapter
  • First Online:
Idiopathic Pulmonary Fibrosis

Part of the book series: Respiratory Medicine ((RM,volume 9))

  • 2142 Accesses

Abstract

Idiopathic pulmonary fibrosis (IPF) was once thought to be a rare disease and has been classically described as a disease that progresses in a “relentless and often insidious manner.” However, recent epidemiologic studies have revealed the true burden of this disease on society and identified risk factors for the development of disease that may ultimately allow for not only disease prevention but also further insight into the pathobiology of this—as of yet—idiopathic disease. At the same time, recent cohort studies and clinical trials have better defined the natural history of this disease. In this manuscript, we will review recently acquired epidemiologic data and summarize the current understanding of the natural history of IPF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646–64.

    Google Scholar 

  2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

    Article  PubMed  Google Scholar 

  3. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, Brown KK. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. Respir Med. 2012;106:588–93.

    Article  PubMed  Google Scholar 

  4. Gordis L. The epidemiologic approach to disease and intervention. In: Gordis L, editor. Epidemiology. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2004. p. 1–14.

    Google Scholar 

  5. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150:967–72.

    Article  PubMed  CAS  Google Scholar 

  6. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810–6.

    Article  PubMed  Google Scholar 

  7. Fernández-Pérez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis. Chest. 2010;137:129–37.

    Article  PubMed  Google Scholar 

  8. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:620–8.

    Article  PubMed  Google Scholar 

  9. King Jr TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75–81.

    Article  PubMed  CAS  Google Scholar 

  10. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–5.

    Article  PubMed  CAS  Google Scholar 

  11. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66:462–7.

    Article  PubMed  CAS  Google Scholar 

  12. Johnston I, Britton J, Kinnear W, Logan R. Rising mortality from cryptogenic fibrosing alveolitis. BMJ. 1990;301:1017–21.

    Article  PubMed  CAS  Google Scholar 

  13. Coultas DB, Hughes MP. Accuracy of mortality data for interstitial lung disease in New Mexico, USA. Thorax. 1996;51:717–20.

    Article  PubMed  CAS  Google Scholar 

  14. Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979–1991. Am J Respir Crit Care Med. 1996;153:1548–52.

    Article  PubMed  CAS  Google Scholar 

  15. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007;176:277–84.

    Article  PubMed  Google Scholar 

  16. Hubbard R, Johnston I, Coultas DB, Britton J. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax. 1996;51:711–6.

    Article  PubMed  CAS  Google Scholar 

  17. Raphael K. Recall bias: a proposal for assessment and control. Int J Epidemiol. 1987;16:167–70.

    Article  PubMed  CAS  Google Scholar 

  18. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304.

    Google Scholar 

  19. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:242–8.

    Article  PubMed  CAS  Google Scholar 

  20. Miyake Y, Sasaki S, Yokoyama T, Chida K, Azuma A, Suda T, et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg. 2005;49:259–65.

    Article  PubMed  Google Scholar 

  21. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc. 2006;3:293–8.

    Article  PubMed  Google Scholar 

  22. Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case–control study of environmental exposure to dust. BMJ. 1990;301:1015–7.

    Article  PubMed  CAS  Google Scholar 

  23. Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet. 1996;347:284–9.

    Article  PubMed  CAS  Google Scholar 

  24. Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposures. Am J Respir Crit Care Med. 1994;150:670–5.

    Article  PubMed  CAS  Google Scholar 

  25. García-Sancho Figueroa MC, Carrillo G, Pérez-Padilla R, Fernández-Plata MR, Buendía-Roldán I, Vargas MH, Selman M. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case–control study. Respir Med. 2010;104:305–9.

    Article  PubMed  Google Scholar 

  26. García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, Navarro C, Pérez-Padilla R, Vargas MH, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med. 2011;105:1902–7.

    Article  PubMed  Google Scholar 

  27. Steele MP, Steer MC, Loyd JE, Brown KK, Herron A, Slifer SH, et al. Clinical and pathologic features of familial pulmonary fibrosis. Am J Respir Crit Care Med. 2005;172:1146–52.

    Article  PubMed  Google Scholar 

  28. Baumgarter KB, Samet JM, Coutas DB, Stidley CA, Hunt WC, Colby TV, Waldron JA. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case–control study. Am J Epidemiol. 2000;152:307–15.

    Article  Google Scholar 

  29. Hubbard R, Cooper M, Antaoniak M, Venn A, Khan S, Johnston I, et al. Risk of cryptogenic fibrosing alveolitis in metal workers. Lancet. 2000;355:466–7.

    PubMed  CAS  Google Scholar 

  30. Pinheiro GA, Antao VC, Wood JM, Wassell JT. Occupational risks for idiopathic pulmonary fibrosis mortality in the United States. Int J Occup Environ Health. 2008;14:117–23.

    PubMed  CAS  Google Scholar 

  31. Gustafson T, Dahlman-Hőglund A, Nilsson K, Ström K, Tornling G, Torén K. Occupational exposure and severe pulmonary fibrosis. Respir Med. 2007;101:2207–12.

    Article  PubMed  Google Scholar 

  32. Mullen J, Hodgson MJ, DeGraff CA, Godar T. Case–control study of idiopathic pulmonary fibrosis and environmental exposures. J Occup Environ Med. 1998;40:363–7.

    Article  PubMed  CAS  Google Scholar 

  33. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162:2213–7.

    Article  PubMed  CAS  Google Scholar 

  34. King TE, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron Jr JA, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001;164:1025–32.

    Article  PubMed  Google Scholar 

  35. King Jr TE, Tooze JA, Schwarz MI, Brown KR, Cherniak RM. Predicting survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164:1171–81.

    Article  PubMed  Google Scholar 

  36. Rudd RM, Prescott RJ, Chalmers JC, Johnston ID, Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax. 2007;62:62–6.

    Article  PubMed  Google Scholar 

  37. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538–42.

    Article  PubMed  Google Scholar 

  38. Nathan SD, Shlobin OA, Wier N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011;140:221–9.

    Article  PubMed  Google Scholar 

  39. Ley B, Collard HR, King Jr TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.

    Article  PubMed  Google Scholar 

  40. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167:962–9.

    Article  PubMed  Google Scholar 

  41. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684–91.

    Article  PubMed  Google Scholar 

  42. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest. 1995;108:305–10.

    Article  PubMed  CAS  Google Scholar 

  43. Du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459–66.

    Article  PubMed  Google Scholar 

  44. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–87.

    Article  PubMed  CAS  Google Scholar 

  45. King Jr TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:92–9.

    Article  PubMed  Google Scholar 

  46. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181:604–10.

    Article  PubMed  CAS  Google Scholar 

  47. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–9.

    Article  PubMed  CAS  Google Scholar 

  48. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo controlled trial. Am J Respir Crit Care Med. 2008;178:948–55.

    Article  PubMed  CAS  Google Scholar 

  49. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–7.

    Article  PubMed  Google Scholar 

  50. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229–42.

    Article  PubMed  CAS  Google Scholar 

  51. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125–33.

    Article  PubMed  CAS  Google Scholar 

  52. Panos R, Mortenson RL, Nicolli SA, King Jr TE. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990;88:396–404.

    Article  PubMed  CAS  Google Scholar 

  53. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King Jr TE, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142:963–7.

    Article  PubMed  Google Scholar 

  54. King Jr TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374:222–8.

    Article  PubMed  CAS  Google Scholar 

  55. Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Fischer A, Solomon JJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J. 2012;39:125–32.

    Article  PubMed  CAS  Google Scholar 

  56. Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med. 2010;104:1035–41.

    Article  PubMed  Google Scholar 

  57. Izbicki G, Ben-Dor I, Shitrit D, Bendayan D, Aldrich TK, Kornowski R, Kramer MR. The prevalence of coronary artery disease in end-stage pulmonary disease: is pulmonary fibrosis a risk factor? Respir Med. 2009;103:1346–9.

    Article  PubMed  Google Scholar 

  58. Kizer JR, Zisman DA, Blumenthal NP, Kotloff RM, Kimmel SE, Strieter RM, et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med. 2004;164:551–6.

    Article  PubMed  Google Scholar 

  59. Ponnuswamy A, Manikandan R, Sabetpour A, Keeping IM, Finnerty JP. Association between ischaemic heart disease and interstitial lung disease: a case control study. Respir Med. 2009;103:503–7.

    Article  PubMed  CAS  Google Scholar 

  60. Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 2008;178:1257–61.

    Article  PubMed  Google Scholar 

  61. Heart disease and stroke statistics – 2004 update. Coronary heart disease, acute coronary syndrome and angina pectoris. Am Heart Assoc. 2004. 6:9–12.

    Google Scholar 

  62. Sode BF, Dahl M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med. 2010;181:1085–92.

    Article  PubMed  Google Scholar 

  63. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis: a population based study. Am J Respir Crit Care Med. 2000;161:5–8.

    Article  PubMed  CAS  Google Scholar 

  64. Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007;101:2534–40.

    Article  PubMed  Google Scholar 

  65. Aubry MC, Myers JL, Douglas WW, Tazelaar HD, Washington Stephens TL, Hartman TE, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc. 2002;77:763–70.

    Article  PubMed  Google Scholar 

  66. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax. 1980;35:171–80.

    Article  PubMed  CAS  Google Scholar 

  67. Carrington CB, Gaensler EA, Coutu RE, FitzGerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med. 1978;298:801–11.

    Article  PubMed  CAS  Google Scholar 

  68. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007;2:e482.

    Article  PubMed  Google Scholar 

  69. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis. PLoS One. 2009;4:e5134.

    Article  PubMed  Google Scholar 

  70. Kondo A, Saiki S. Acute exacerbation in idiopathic interstitial pneumonia (IIP). In: Harasawa M, Fukuchi Y, Morinari H, editors. Interstitial pneumonia of unknown etiology. Tokyo: University of Tokyo Press; 1989. p. 33–42 [Intractable Diseases Research Foundation Publication No. 27].

    Google Scholar 

  71. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three cases. Chest. 1993;103:1808–12.

    Article  PubMed  CAS  Google Scholar 

  72. Colby TV. Interstitial lung disease. In: Colby TV, Lombard CM, Yousem SA, et al., editors. Atlas of pulmonary surgical pathology. Philadelphia, PA: WB Saunders; 1991. p. 227–306.

    Google Scholar 

  73. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King Jr TE, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–43.

    Article  PubMed  Google Scholar 

  74. Kondoh Y, Taniguchi H, Katsuta T, Kataoka K, Kimura T, Nishiyama O, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27:103–10.

    PubMed  CAS  Google Scholar 

  75. Song JW, Hong SB, Lim CM, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors, and outcome. Eur Respir J. 2011;37:356–63.

    Article  PubMed  CAS  Google Scholar 

  76. Noth I, Anstrom KJ, Clavert SB, de Andrade J, Flaherty KR, Glazer C, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186:88–95.

    Article  PubMed  CAS  Google Scholar 

  77. Bitterman PB, Rennard SI, Keogh BA, Wewers MD, Adelberg S, Crystal RG. Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members. N Engl J Med. 1986;314:1343–7.

    Article  PubMed  CAS  Google Scholar 

  78. Rosas IO, Ren P, Avila NA, Chow CK, Franks TJ, Travis WD, et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:698–705.

    Article  PubMed  Google Scholar 

  79. El-Chemaly S, Ziegler SG, Wilson K, Gahl WA, Moss J, Gochuico BR. Familial pulmonary fibrosis: natural history of preclinical disease. Am J Respir Crit Care Med. 2010;181:A2980.

    Google Scholar 

  80. Sakamoto K, Taniguchi H, Kondoh Y, Ono K, Hasegawa Y, Kitaichi M. Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease. Eur Respir Rev. 2009;18:129–32.

    Article  PubMed  CAS  Google Scholar 

  81. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005;128:3310–5.

    Article  PubMed  Google Scholar 

  82. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27:143–50.

    Article  PubMed  CAS  Google Scholar 

  83. Chida M, Ono S, Hoshikawa Y, Kondo T. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg. 2008;34:878–81.

    Article  PubMed  Google Scholar 

  84. Fukushima K, Kawabata Y, Takashi U, Yuzuki N. Prognosis of possible development into diffuse interstitial pneumonia for 127 patients with localized usual interstitial pneumonia. Nihon Kokyuki Gakkai Zasshi. 1999;37:177–82 [Japanese].

    Google Scholar 

  85. Araya J, Kawabata Y, Jinho P, Uchiyama T, Ogata H, Sugita Y. Clinically occult subpleural fibrosis and acute interstitial pneumonia a precursor to idiopathic pulmonary fibrosis. Respirology. 2008;13:408–12.

    Article  PubMed  Google Scholar 

  86. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012;185:1147–53.

    Article  PubMed  Google Scholar 

  87. Fell CD. Idiopathic pulmonary fibrosis: phenotypes and comorbidities. Clin Chest Med. 2012;33:51–7.

    Article  PubMed  Google Scholar 

  88. Nathan SD, Nobel PW, Tudor RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med. 2007;175:875–80.

    Article  PubMed  Google Scholar 

  89. Kawut SM, O’Shea MK, Bartels MN, Wilt JS, Sonett JR, Arcasoy SM. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med. 2005;99:1431–9.

    Article  PubMed  Google Scholar 

  90. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007;131:657–63.

    Article  PubMed  Google Scholar 

  91. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129:746–52.

    Article  PubMed  Google Scholar 

  92. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128:2393–9.

    Article  PubMed  Google Scholar 

  93. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26:586–93.

    Article  PubMed  CAS  Google Scholar 

  94. Cottin V, Le Pavec J, Prévot G, Mal H, Humbert M, Simonneau G, Cordier JF, GERM”O”P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35:105–11.

    Article  PubMed  CAS  Google Scholar 

  95. Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome. Chest. 2012;141:222–31.

    Article  PubMed  Google Scholar 

  96. Mejía M, Carrillo G, Rojas-Serrano J, Estrada A, Suárez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009;136:10–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Calgary, Adult Respirology Residency Program, Rockyview General Hospital, Calgary, AB, Canada

    Olga Tourin M.D.

  2. Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson Street, Denver, CO, 80238, USA

    Jeffrey J. Swigris D.O., M.S.

  3. Division of Pulmonary and Critical Care Medicine, National Jewish Health, Interstitial Lung Disease Program and Autoimmune Lung Center, 1400 Jackson Street, Denver, CO, 80238, USA

    Amy L. Olson M.D., M.S.P.H.

Authors
  1. Olga Tourin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey J. Swigris D.O., M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amy L. Olson M.D., M.S.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy L. Olson M.D., M.S.P.H. .

Editor information

Editors and Affiliations

  1. Dept. Internal Medicine, Sect. Allergy Pulmonary & Critical Care Med., University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA

    Keith C. Meyer

  2. Advanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, Virginia, USA

    Steven D. Nathan

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Tourin, O., Swigris, J.J., Olson, A.L. (2014). Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease. In: Meyer, K., Nathan, S. (eds) Idiopathic Pulmonary Fibrosis. Respiratory Medicine, vol 9. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-682-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-682-5_2

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-681-8

  • Online ISBN: 978-1-62703-682-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation